Prophylactic Trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate

Trimethoprim-sulfamethoxazole (TMP/SMX) is used as prophylaxis against Pneumocystis jiroveci during chemotherapy. Many groups recommend withholding TMP/SMX during high-dose methotrexate (HDMTX) for concerns that it will delay methotrexate clearance. We compared methotrexate exposure following HDMTX...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Pediatr Hematol Oncol
Päätekijät: Watts, Courtney S., Sciasci, Joseph N., Pauley, Jennifer L., Panetta, John C., Pei, Deqing, Cheng, Cheng, Christensen, Caroline M., Mikkelsen, Torben S., Pui, Ching-Hon, Jeha, Sima, Relling, Mary V.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955728/
https://ncbi.nlm.nih.gov/pubmed/27322715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPH.0000000000000606
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia